Suspension aerosol formulations of pharmaceutical products

• US 20050031548A1
• Filed: 09/03/2004
• Published: 02/10/2005
• Est. Priority Date: 02/03/1990
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Promeco SA de CV (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Promeco SA de CV (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Daab, Ottfried, Weil, Hans-Hermann
• Granted Patent: US 7,160,538 B2
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61K 9/124 characterised by the propellant
• CPC Class Codes: C09K 3/30 for aerosols aerosol containers B65D83/14

Abstract

Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME.

Claims

1-11. -11. (canceled).

12. In a pharmaceutical formulation for administration of micronized or powdered drug to the respiratory tract of a warm-blooded animal via inhalation wherein propellant gases as employed, the improvement which comprises 1,1,1,2,3,3,3-heptafluoropropane as the sole propellant gas.